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Summary 
Remnants oflipoproteins, intestinal chylomicrons, and very low density lipoproteins (VLDL), 
are rapidly cleared from plasma  and enter hepatocytes. It has been suggested that remnant lipo- 
proteins are initially captured in the space of Disse  by heparan sulfate proteoglycans (HSPGs), 
and that their subsequent internalization into hepatocytes is mediated by members of the LDL- 
receptor gene family. Similarly to lipoprotein remnants, malaria sporozoites are removed from 
the blood circulation by the liver within minutes after injection by Anopheles mosquitoes. The 
sporozoite's surface is covered by the circumsporozoite protein (CS), and its region II-plus has 
been  implicated in  the  binding  of the  parasites  to  glycosaminoglycan chains  of hepatocyte 
HSPGs. Lactoferrin, a protein with antibacterial properties found in breast milk and neutrophil 
granules, is also rapidly cleared from the circulation by hepatocytes, and can inhibit the hepatic 
uptake  of lipoprotein remnants.  Here we provide evidence that sporozoites, lactoferrin, and 
remnant lipoproteins are cleared from the blood by similar mechanisms.  CS, lactoferrin, and 
remnant lipoproteins compete in vitro and in vivo for binding sites on liver cells.  The rele- 
vance of this binding event for sporozoite infectivity is highlighted by our demonstration that 
apoliprotein E-enriched [3-VLDL and lactoferrin inhibit sporozoite invasion of HepG2 cells. 
In  addition,  malaria  sporozoites are  less infective in  LDL-receptor knockout  (LDLR-/-) 
mice maintained on a high fat diet, as compared with littermates maintained on a normal diet. 
We conclude that the clearance oflipoprotein remnants and sporozoites from the blood is me- 
diated by the same set of highly sulfated HSPGs on the hepatocyte plasma  membrane. 
C 
hylomicron and very low density lipoprotein (VLDL) ~ 
remnants, generated from the metabolism of intestinal 
chylomicrons and hepatic VLDL, are enriched in apolipo- 
protein E  (apoE) and rapidly cleared from the  circulation 
by the liver (for review see references 1 and 2).  Clearance 
and liver uptake are apoE dependent (3-8). On the basis of 
a large body of evidence from cell culture  (9,  10)  and in 
vivo (11)  studies it has been postulated that the initial se- 
questration of lipoprotein particles is  mediated mainly by 
hepatic  heparan  sulfate  proteoglycans  (HSPGs),  and  that 
this  facilitates their subsequent  interiorization by the  low 
density lipoprotein receptor (LDLR), and the LDLR-related 
1Abbreviations used in this paper: apoE, apoliprotein  E; CS, circumsporozo- 
ite  protein; EEF, exoerythrocytic forms; GAG, glycosaminoglycan; 
HPRT, hypoxanthine  phosphorybosyl  transferase; HSPG, heparan sulfate 
proteoglycan; LDLR, low density lipoprotein receptor; LRP, LDLR- 
related protein; RT,  reverse transcriptase; TBS, Tris-buffered saline; 
TRAP/SSP2, thrombospondin-related  adhesive protein/sporozoite  sur- 
face protein 2; VLDL, very low density  lipoprotein. 
protein  (LRP)  (12).  Lactoferrin also  binds  to  HSPGs and 
LRP (12-14), and competes with remnant lipoproteins for 
hepatic clearance from the circulation and for internaliza- 
tion by hepatocytes (15,  16). 
There are  intriguing  similarities  between  the  clearance 
patterns of the major surface protein of malaria sporozoites, 
the circumsporozoite protein (CS)  (17),  and remnant lipo- 
proteins.  Within  minutes  after intravenous  injection into 
mice, CS accumulates in the space of Disse  on the plasma 
membrane of hepatocyte microvilli (18).  Heparinase treat- 
ment of liver sections that have been incubated with  CS, 
and  other  in  vitro  experiments  using  hepatocytes  and 
HepG2  cells  as  targets,  demonstrate  that  CS  binds  to 
HSPGs (19,  20). The proteoglycan-binding portion of CS 
(19,  21)  is  region  II-plus  (22),  a  stretch  of amino  acids 
highly conserved in all species of malaria parasites  (23). The 
region II-plus motif is also found in thrombospondin-related 
adhesive  protein/sporozoite  surface  protein  2  (TRAP/ 
SSP2),  another surface protein of malaria sporozoites (24, 
25) that binds to cell surface HSPGs  (26,  27).  Within re- 
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Figure  1.  Heparin  binding motifs of P. falciparum, P.  berghei, and P. 
yoelii CS, apoE, and lactoferrin. Boldface italics indicate amino acid resi- 
dues of CS protein required for binding to HSPGs (22). Amino acid resi- 
dues forming a similar motif in the heparin-binding  domains of apoE (30, 
31) and lactoferrin (16, 28, 29) are also highlighted. 
gion II-plus, the positively charged  amino acids and inter- 
spersed  hydrophobic  residues  in  its  COOH-terminal  end 
(see Fig.  1) are critical for binding to HSPGs (22). An ionic 
interaction between these basic residues and the negatively 
charged  sulfate moieties of HSPGs is most likely involved 
since chlorate,  a metabolic inhibitor of sulfation, markedly 
decreases  CS  binding to  HepG2  cells  (Sinnis,  P.,  manu- 
script in preparation). As shown in Fig.  1, a similar motif is 
found in the  heparin-binding domains of apoE  and lacto- 
ferrin  (16,  28-31).  In this paper  we  provide  experimental 
evidence  in  support  of  the  hypothesis  that  CS,  malaria 
sporozoites,  remnant lipoproteins,  and lactoferrin are  rec- 
ognized by the same set of cell surface HSPG molecules in 
vitro  and  are  cleared  from  the  circulation  by  hepatocyte 
HSPGs in vivo. 
Materials and Methods 
Materials.  CS  protein,  the  Escherichia coli-derived  recombi- 
nant CS27IVC (27-123 [NANPNVDP]3[NANP]2~300-411), rep- 
resents the complete Plasmodiumfalciparum  CS sequence from the 
T4 isolate, except that the hydrophobic NH2- and COOH-ter- 
minal amino acids 1-26 and 412-424 have been deleted and five 
histidine residues have been added to the COOH terminus to fa- 
cilitate purification (32).  The recombinant protein used in these 
studies  was  generously provided by Dr.  Bela  Takacs  (F.  Hoff- 
mann-La Roche Ltd., Basel,  Switzerland). Recombinant human 
apoE  (E3  isoform), obtained from E.  Coil  (33),  was a gift from 
Dr. Tikva Vogel (Biotechnology General, Rehovot, Israel).  mAb 
2AI0 is directed against an epitope contained in the (NANP)n re- 
peat domain of P. falciparum  CS  (34)  and mAb 2E6,  a gift from 
Dr. Moriya Tsuji (New York University Medical Center), reacts 
with the liver stage of Plasmodium berghei (35).  ]3-migrating VLDL 
(]3-VLDL; d <1.006 g/ml) was prepared from the plasma of rab- 
bits fed for 4 d with a 2% (wt/wt)  cholesterol,  10% (vol/wt) co- 
conut oil  diet,  as  described  (36),  ApoE-enriched ]3-VLDL  was 
prepared by coincubating apoE and [3-VLDL at a ratio of 1:1  for 
1 h at 37~  before use. 
Mice.  LDLR-/-  mice were  created by targeted  gene dis- 
ruption as  described  (37).  All other mice,  including apoE-/- 
mice, were purchased from The Jackson Laboratory (Bar Harbor, 
ME).  Mice on special diets were fed either normal mouse chow 
(Purina rodent chow #5001;  Purina Mills, St.  Louis, MO)  or a 
1.25% cholesterol, high saturated fat diet as described (38) for 5 d 
before  each  experiment.  Briefly,  the  high  fat  diet  consisted  of 
three parts normal chow mixed with one part mouse chow con- 
taining  cholesterol,  cocoa  butter,  casein,  and  sodium  cholate 
(TD78399 from Harlan Teklad Premier Laboratory Diets, Madi- 
son,  WI).  The  final high  fat  diet  contained  1.25%  cholesterol, 
7.5%  (wt/wt)  cocoa  butter,  7.5%  casein, and 0.5%  (wt/wt)  so- 
dium cholate. 
Binding of CS to HepG2 Cells.  Assays were carried out as de- 
scribed (22).  Briefly, HepG2 cells were grown in 96-well plates, 
fixed with 4% paraformaldehyde,  and blocked with  1% BSA in 
Tris-buffered saline (TBS/BSA). When lactoferrin or transferrin 
(both from Sigma Chemical Co., St.  Louis, MO) was used as an 
inhibitor, cells were coincubated with 2.5 btg/ml of CS and the 
inhibitor at the indicated concentrations for  1 h  at 37~  After 
washing,  cells  were  incubated  with  12SI-labeled  mAb  2At0, 
washed,  and counted in a  gamma  counter.  In the  experiments 
with apoE, [3-VLDL, and apoE-enriched [3-VLDL, the inhibitors 
were preincubated with the cells for 30 rain and then CS protein 
was added to a final concentration of 2.5 btg/ml. CS and the in- 
hibitor were then coincubated with the cells for 45 rain at 37~ 
and the assay was processed as above. 
Clearance Experiments.  Mice were anesthetized with intraperi- 
toneal sodium pentobarbital injection (-~  Izg/gm) and injected 
intravenously with 7  ￿  10  s cpm of 12Sl-labeled CS,  prepared as 
described  (18)  and representing N0.1  b~g of protein in 200  btt 
TBS with 0.1% BSA. At the indicated time points, 50-bd blood 
samples were collected by retroorbital puncture and counted in a 
gamma counter. To study the  effect of lactoferrin on CS clear- 
ance, radiolabeled CS was injected 5 nfin after the injection of 3 mg 
of lactoferrin  in  250  bL1  TBS  or  TBS  alone.  CS  clearance  in 
LDLR-/-  and apoE-/-  mice was performed 5 d after the an- 
imals were put on a high fat  diet, and plasma cholesterols were 
measured on the day of the clearance experiment using an assay 
kit obtained from Sigma Chemical Co. When organs were har- 
vested for counting, the mice were injected with 4 ￿  l0  s cpm of 
CS; 2  min later, the mice were  killed, exsanguinated, and their 
organs were  removed,  rinsed in TBS,  and counted in a gamma 
counter. 
Assw for Sporozoite Infectivity In  Vitro.  This was performed as 
described  (39,  40)  with modifications as described (21).  Briefly, 
HepG2 cells were plated in chamber slides,  grown for 2  d,  and 
incubated for 15 rain with each inhibitor before 50,000 P. berr 
sporozoites  were  added  to  each  well.  2  h  after  parasites  were 
added, the cells were washed and then grown for an additional 2 d 
after which they were fixed with methanol and stained with mAb 
2E6,  followed by goat anti-mouse Ig conjugated to  horseradish 
peroxidase and 3,3'-diaminobenzidine. The number ofexoeryth- 
rocytic forms  (EEF)  in each well were  counted microscopically 
using a ￿  20 light microscope objective. 
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Figure  2.  Inhibition of CS  binding to  HepG2 cells by lactoferrin, 
apoE, and apoE-enriched ~3-VLDL.  (A) Paraformaldehyde-fixed  HepG2 
cells in 96-well plates were coincubated with CS and either lactoferrin 
(circles) or transferrin (squares) for 1 h. After washing, cells were incubated 
with iodinated mAb 2A10, washed and bound antibody was counted in a 
gamma counter. Shown is percent inhibition of binding of CS to HepG2 
cells in the presence of inhibitor compared with results obtained in the 
absence of inhibitor. Each inhibitor concentration  was assayed in triplicate 
and standard deviations  were not greater than 5%. (/3) The assay was car- 
ried out as above except that cells were preincubated  with apoE (open tri- 
angles), [8-VLDL (closed circles), or apoE-enriched ~-VLDL (dosed triangles) 
for 30  rain. CS  was then added for an additional 45  rain, cells were 
washed, and bound CS was quantified  as above. (Inset) Results of a similar 
Quantitative  PCR  Assay  for  Sporozoite  Infectivity  In  Vivo. 
LDLP,-/-  mice were fed either a normal or high fat diet for 5 d 
and  then  injected  intravenously with  7,500  Plasmodium  yoelii 
sporozoites.  Measurement of parasite rtLNA was then performed 
using a competitive PCR assay as described  (41). Briefly, 40 h af- 
ter sporozoite  injection, the mice were killed,  their livers were 
harvested,  frozen in liquid nitrogen, crushed,  added to  8 ml of 
RNAzol  (Biotecx  Laboratories  Inc.,  Houston,  TX),  and  vor- 
texed.  1 rnl of liver homogenate was used for RNA purification 
performed according to manufacturer's instructions (Biotecx Lab- 
oratories,  Inc.).  Reverse transcriptase  (RT)  and PCP, reactions 
were  performed using a  RT-PCR kit  (Perkin-Elmer, Branch- 
burg, NJ).  P-NA was quantified by absorbance  at 260 nm, and 
RT reactions  were performed with  1 gtg of I<NA and random 
hexamers  supplied by the manufacturer. PCP,. of this cDNA was 
perfonned using parasite rRNA primers that recognize P. yoelii- 
specific sequences  within the  18S rRNA (5'-CGGGATCCAG- 
GATGTATTCGCTTTAT-3'  and 5'-GGGGTACCTTCTTGT- 
CCAACCAATTC-3') in the presence  of a competitor template 
constructed by insertion of a 355-bp lambda DNA fragment into 
the  cloned 393-bp  rP,  NA  parasite  amplification product.  The 
competitor molecule is 748 bp in length and the parasite target is 
393 bp.  Mouse  hypoxanthine  phosphorybosyl transferase (HPP, T) 
primers and competitor were  used  as positive  controls to  assess 
the  efficiency  of R.T  reactions  as  described  (42). Amplification 
products were analyzed by electrophoretic separation  on 2% aga- 
rose  in 0.04  M  Tris-acetate,  0.001  M  EDTA, stained  with 0.5 
~g/ml ethidium bromide and photographed  under long wave- 
length UV light. 
Results 
To examine the relationship between hepatocyte-bind- 
ing  sites  for  CS  and  apoE/lactoferrin,  we  performed  in 
vitro competition experiments using HepG2 cells as targets. 
We have previously shown that CS binds to these cells in a 
saturable fashion, and that binding is abolished when cells 
are treated with heparitinase (19). Fig. 2 illustrates the inhi- 
bition of CS  binding to  HepG2  cells  by lactoferrin  and 
apoE. Between 80 and 90% inhibition is obtained with 1.6 
~M lactoferrin. Transferrin, a protein with 59% identity to 
lactoferrin but lacking heparin-binding  domains, has no ef- 
fect on CS binding even at much higher concentrations. In 
Fig.  2  B,  we  compare  the  abilities of [3-VLDL  (isolated 
from plasma of hyperlipidemic rabbits and used as  an ex- 
perimental  source  of  lipoprotein  remnants),  apoE,  and 
apoE-enriched [3-VLDL to inhibit CS binding to  HepG2 
cells.  CS binding is inhibited by >80% with 1 btM recom- 
binant apoE. While [3-VLDL alone is inactive, upon addi- 
tion of apoE,  it inhibits CS  binding in a  dose-dependent 
fashion. This finding is in agreement with previous studies 
that have shown that i3-VLDL must be enriched in apoE in 
order to  bind with high avidity to  cell surface proteogly- 
cans and to LRP (9,  10, 38, 43). At low concentrations, the 
experiment using lower concentrations  ofapoE (open triangles) and apoE- 
enriched 13-VLDL (closed triangles). Each inhibitor concentration  was as- 
sayed in triplicate  and standard deviations  were less than 5%. 
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Percent 
Experiment  Inhibitor*  No. of EEF*  inhibition~ 
l  Medium alone*  251,273,305~ 
Transferrin  500 Ixg/ml  20(/,281,254  11 
Lactoferrin  500 Ixg/ml  63,67,8(/  74 
Lactoferrin  250 b~g/ml  77,100,114  64 
Lactoferrin  125 Ixg/ml  138,137,19{i)  43 
Medium alone  779,730,725 
Transferrin  500 jxg/ml  493,686,736  14 
Lactoferrin  500 Ixg/ml  274,266,27{)  63 
Lactoferrin  250 I.tg/ml  462,476,425  38 
Lactoferrin  125 txg/ml  479,515,535  31 
Medium alone  459,488,424 
ApoE and [3-VLDL 250 }xg/ml  112,138,180  68 
ApoE and ~-VLDL 125 txg/ml  220,253,265  46 
ApoE and [3-VLDL 62 Ixg/ml  323,358,357  23 
Medium alone  928,958,1068 
~-VLDL 250 Ixg/ml  t053,930,984 
13-VLDL 125 txg/ml  1051,981,981 
ApoE and 13-VLDL 250 Ixg/ml  486,454,459  51 
ApoE and [3-VLDL 125 Ixg/ml  769,938,792  15 
Medium alone  166, 114, 149 
ApoE and [3-VLDL 250 Ixg/ml  41,59,52  64 
ApoE and [B-VLDL 125 txg/ml  69,105,122  31 
ApoE and [3-VLDL 62 }xg/ml  107,110,111  24 
*  HepG2 cells in chamber slides were incubated for 15 rain with each inhibitor before 50,000 P. berehei sporozoites were added to each well. 2 h after 
parasites were added, the cells were washed and grown for an additional 2 d at which time they were fixed and stained. 
~The number of EEF per 20 fields under ￿  magnification in triplicate wells. 
~Calculated using the mean number of parasites in the control group, in which sporozoites were allowed to invade in the presence of medium alone, 
and the mean from the experimental group. 
inhibitory  activity  of apoE-enriched  [3-VLDL  is  higher 
than that of apoE alone  (Fig. 2  B  inset).  The increased ac- 
tivity of apoE-enriched [3-VLDL over apoE alone is proba- 
bly  greater  than  that  shown  in  Fig.  2  B,  since  the  molar 
concentration of apoE after incorporation into lipoprotein 
particles is lower than that of free apoE. Previous studies (9, 
10,  12)  have  shown  that  the  binding  of apoE-enriched 
13-VLDL to HepG2  cells  is inhibited  by lactoferrin,  or by 
prior heparitinase  treatment  of the  ceils.  Our findings,  to- 
gether  with  these  data,  indicate  that  CS,  lactoferrin,  and 
apoE compete for the same set of HSPGs on the surface of 
HepG2 cells. 
Next,  we  asked whether  lactoferrin  and  apoE-enriched 
13-VLDL could prevent the infection of HepG2 cells by P. 
berghei, a rodent malaria parasite. Table 1 shows that 3.2 IxM 
(250  txg/ml)  lactoferrin,  but not an  equivalent  amount  of 
transferrin,  inhibits sporozoite invasion by ~50%. Whereas 
~-VLDL alone is inactive,  after its  enrichment with apoE, 
it inhibits sporozoite invasion of HepG2 cells by 50-68%. 
Lactoferrin and  renmant  lipoproteins  compete with  CS 
not only for binding to hepatocytes in vitro, but also for CS 
clearance by the  liver.  In Fig.  3  A  we  show  that  the  re- 
moval of CS from the circulation is delayed when mice are 
preinjected  with 3  mg of lactoferrin.  To verify that lacto- 
fen'in was inhibiting clearance of CS because it was COlnpeting 
with  CS for hepatic  binding  sites,  we  performed  another 
experiment  in  which  mice  preinjected  with  lactoferrin 
were killed after radiolabeled CS injection and their organs 
were harvested  and  counted.  As shown in  Fig.  4 A,  mice 
preinjected  with  3  nag  of lactoferrin  had  24%  of the  in- 
jected counts in the liver, whereas control mice preinjected 
with  either 3 nag of transferrin or buffer alone had 60% of 
the  injected  counts  in  their  livers.  Most  of the  remaining 
counts were found in the blood,  and ~1()%  of the  counts 
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Figure  3.  Lactoferrin  and remnant lipoproteins inhibit CS  clearance 
from the circulation.  (A) Mice were anesthetized and intravenously in- 
jected with 3 mg of lactoferrin in 250 p.1 of TBS (closed  circles)  or with 
buffer alone (open circles).  125I-labeled CS was injected intravenously 5 min 
later and 50-pJ blood samples were taken at the indicated time points. Val- 
ues are expressed as a percentage of the radioactivity  present in the plasma 
30 s after CS injection￿9 There were six mice in each group and error bars 
show the range of absolute  values measured.  (B) LDLR-/-  mice were 
fed either normal mouse chow (open  circles)  or a 1.25% cholesterol,  high 
saturated  fat diet (closed  circles)  for 5  d  before CS  injection. Mice were 
anesthetized and measurement of CS clearance  from the circulation was 
performed as above. Each group contained five mice and this experiment 
was  performed  three times with identical  results.  Error bars  show  the 
range of absolute  values measured.  (Inset)  LDLR-/-  mice (closed circles) 
and LDLR+/+  matched background controls (C57B6x129F2;  open  cir- 
cles),  both maintained on a normal diet were intravenously injected with 
radiolabeled  CS and clearance  from the circulation was measured as de- 
scribed  above. Each group contained five mice and this experiment was 
repeated twice with identical results. (C) ApoE -/-  mice were fed nor- 
real mouse chow (open  triangles)  or a 1.25% cholesterol,  high saturated  fat 
diet ({,pen  circles)  for 5  d before radiolabeled  CS  injection. ApoE  +/+ 
mice of the same background and age as the knockout mice (closed circles) 
were fed normal mouse chow. Mice were anesthetized and CS clearance 
from the circulation was perfomled as above. There were five mice per 
group and this experiment was performed twice with identical results. 
were evenly distributed in various organs without  any focal 
accumulation  (data not shown). 
To study the effect oflipoprotein  remnants on CS  clear- 
ance,  we  used LDLR-/-  mice. When  fed a  normal diet, 
these mice accumulate  LDL,  but not lipoprotein remnants, 
and their total plasma cholesterol levels are slightly elevated 
(-----250 mg/dl; 37, 38).  In preliminary studies we found that 
there was no significant difference in CS clearance between 
LDLR-/-  and LDLR+/+  mice  fed normal  diets  (inset, 
Fig.  3  B).  When  LDLR-/-  mice  are  fed  a  diet  high  in 
saturated fat,  their plasma  cholesterol levels rise because  of 
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the  accumulation  of lipoprotein  remnants  and  LDL  (37, 
38).  As  shown  in  Fig.  3  B,  CS  clearance  was  delayed  in 
LDLR-/-  mice  fed  a  high  fat  diet  (plasma  cholesterol 
1,120  -  79  mg/dl)  when  compared  with LDLR-/-  lit- 
termates  fed  a  normal  diet  (plasma  cholesterol  179  -+  31 
mg/dl). To verify that the delay in CS clearance was due to 
an inhibition of CS binding in the liver, we performed an- 
other experiment in which the mice were killed after radio- 
labeled  CS  injection  and  their  organs  were  harvested  and 
counted.  When  LDLR-/-  mice  fed a  high fat diet were 
killed 2  min after radiolabeled CS injection, 43% of the in- 70 
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Figure 4.  Lactoferrin  and remnant lipoproteins inhibit CS clearance to 
the liver. (A) Mice were injected with either 3 mg oflactoferrin or trans- 
ferrin in 200 p,l of TBS or with buffer alone. 5 min later they were in- 
jected with 12SI-labeled  CS and then killed 2 min later. The mice were 
exsanguinated, their organs harvested, and the radioactivity in the organs 
was determined. Values are expressed as a percentage of the radioactivity 
injected. There were three mice in each group and error bars show the 
range of absolute values measured. (B) LDLR-/- mice were fed either 
normal mouse chow or a 1.25%, cholesterol, high saturated Fat diet for 5 d. 
On day 5, the mice were injected with t2Sl-labeled  CS and 2 rain later the 
mice were  killed, exsanguinated, and their organs were  harvested and 
counted in a gamma counter. Values are expressed as a percentage of the 
radioactivity injected. There were six mice in each group. 
jected counts were found in the liver, whereas 63%  of the 
injected counts were found in the livers of mice fed a nor- 
mal diet (Fig. 4/3).  Of note, the inhibition of CS clearance 
observed in  mice  preinjected with  lactoferrin was  greater 
than that observed in LDLR-/-  mice fed a high fat diet 
(compare Fig. 3, A  and/3). This can be explained by differ- 
ences in the plasma concentrations of the inhibitors. In the 
experiments with lactoferrin, plasma levels of the inhibitor 
were ,'o2 mg/ml, whereas in LDLR-/-  mice maintained 
on a high fat diet, plasma apoE levels increase two- to four- 
fold, i.e., from 0.08 to 0.4 mg/ml (38, 44). 
It  could  be  argued  that  the  delay  in  CS  clearance  in 
LDLR-/-  mice fed a high fat diet is not due to CS com- 
petition with  apoE-enriched remnant  particles, but  rather 
to secondary, nonspecific effects of high plasma cholesterol 
levels. To  exclude this possibility, we compared CS  clear- 
ance  in  apoE  knockout  mice  (apoE-/-)  and  controls. 
ApoE-/-  mice fed a normal diet have plasma cholesterol 
levels between  500  and  700  mg/dl.  When  fed a  high  fat 
diet, their cholesterol levels rise to over 2,000 mg/dl due to 
the  accumulation  of apoE-deficient  remnant  lipoproteins 
(7, 8, 38). As shown in Fig. 3  C, CS clearance is not signif- 
icantly different between apoE-/-  mice fed a normal diet 
(plasma cholesterol 726  +  62 mg/dl)  and those fed a high 
fat diet (plasma cholesterol 2,159  +  496  mg/dl).  In addi- 
tion,  CS  clearance in  apoE+/+  mice  (plasma cholesterol 
<130 mg/dl) was not significantly different from clearance 
in apoE-/-  mice. Thus, if apoE is missing, high levels of 
circulating remnant lipoproteins do not  compete with  CS 
for binding to liver HSPGs. 
Finally, we tested whether we could inhibit malaria in- 
fection in a rodent model of the disease. Using a quantitative 
PCR  assay, we compared the amounts of parasite rRNA in 
the  livers  of LDLR-/-  mice  infected  with  Plasmodium 
sporozoites 40  h  earlier. We found  that LDLR-/-  mice 
fed a high fat diet had eightfold less parasite rRNA in their 
livers than LDLR-/-  littermates fed a normal diet (Fig. 5). 
Discussion 
Here  we  show  that  CS,  lactoferrin,  and  remnant  lipo- 
proteins  compete  for  the  same  hepatic-binding sites.  Al- 
though  the  nature  of the  liver molecules involved in  the 
rapid clearance of these ligands from the circulation has not 
been  unequivocally  established,  a  large  body  of evidence 
derived from in vitro (for a review see reference 12)  and in 
vivo (11)  studies suggest that they are HSPGs.  This idea is 
supported by the  recent  observation  that  the  injection of 
heparinase into mice delays the clearance oflactoferrin and 
lipoprotein remnants  from  the  circulation  (45).  Our  data, 
demonstrating that CS can compete with these physiologi- 
cal ligands for clearance by hepatocytes, provide additional 
support for this hypothesis since injected CS binds almost 
exclusively to  the  microvilli on  the  basolateral domain  of 
hepatocytes (18)  and in vitro, this binding is completely elim- 
inated when liver sections are treated with heparitinase (19). 
Although HSPGs are widely distributed in animal tissues, 
CS, apoE, and lactoferrin are retained almost exclusively in 
950  Remnant Lipoproteins Inhibit Malaria Sporozoite Invasion Figure 5.  Remnant lipoproteins inhibit infectivity of P. yoelii sporozo- 
ites in mice. LDLR-/-  mice were fed either a normal or high fat diet 
(four mice per group) for 5 d and then injected intravenously with 7,500 
P. yoelii sporozoites. 40 h after sporozoite injection, the mice were assayed 
for malaria infection by measurement of  parasite rRNA using quantitative 
RT-PCR.  Shown are PCR products of reactions using parasite rRNA 
primers and (A) 1 pg or (B) 5 pg of  parasite rRNA competitor. (C) prim- 
ers for mouse HPRT and 0.l pg of the HPRT  competitor were used. 
The competitor band is not visible in PCRs  using cDNA from the four 
mice fed a normal diet, whereas faint bands can be seen in reactions using 
cDNA from the four mice fed a high fat diet (A). When the amount of 
competitor in the reactions is increased (B), the competitor band is clearly 
more abundant than the parasite target in the mice fed the high fat diet, 
and is less than or equal to the parasite target in mice fed normal chow. In 
reactions using HPRT primers and competitor, an equal ratio of the in- 
tensities of the competitor and target bands for all mice, regardless  of diet, 
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the liver. This can be explained in part by the accessibility 
of hepatocyte HSPGs to the circulation since the endothe- 
lial cells lining  the  hepatic  sinusoids  have  open  fenestra- 
tions, allowing for direct contact between hepatocytes and 
the blood circulation. However,  endothelial cells of other 
organs  also  have  contact  with  the  circulation  and  bear 
HSPGs on their plasma membranes.  Structural diversity of 
HSPG glycosaminoglycan (GAG) chains, generated by post- 
polymeric modifications such as de-N-acetylation, N-sulfa- 
tion  and  O-sulfation, is associated with  defined biological 
functions  (for a  review see reference  46)  and may explain 
the selective binding of CS, apoE,  and lactoferrin to hepa- 
tocyte HSPGs.  Recent studies have demonstrated that he- 
patic HSPGs have levels of N- and O-sulfation that are at 
least 50% higher than most other HSPGs (47), whereas the 
levels of N- and O-sulfation of endothelial cell HSPGs are 
low (47, 48). Although the structure of the GAGs that bind 
CS and the other ligands is not known,  the degree ofsulfa- 
tion ofHSPGs of HepG2 cells is critical for CS binding and 
sporozoite invasion (Sinnis, P.,  manuscript in preparation), 
suggesting  that  these  ligands  can  indeed  discriminate  be- 
tween different GAG chain structures. 
The present studies also demonstrate that remnant lipo- 
proteins  inhibit  sporozoite  infectivity in  mice.  This  sug- 
gests, for the first time, that the in vitro demonstration that 
HSPGs are the hepatic-binding sites for CS, is of relevance 
in malaria infection. The precise step at which CS binding 
to hepatic HSPGs is required during sporozoite invasion of 
hepatocytes is not known,  but the clearance data presented 
here and elsewhere (18) suggest that CS mediates the initial 
arrest of the parasites in the liver. Previous studies demon- 
strating that only multimers of CS  bind in a  stable fashion 
to HSPGs (21, 22), suggest that the adhesion ofsporozoites 
to  hepatocytes involves a  multimeric  interaction  between 
sporozoite  CS,  which  forms  a  dense  coat  on  the  parasite 
surface (49),  and hepatocyte HSPGs, which are present on 
the cell surface in the range of 4  ￿  106 molecules per cell 
(50,  51).  The  abundance  of HSPG  molecules  on  the  cell 
surface,  together with  the large number  of hepatocytes in 
the liver (1011),  create a  high  capacity capture system that 
can, in part, explain the well known efficiency of sporozo- 
ite infection. TRAP/SSP2, which also contains a region II- 
plus  motif,  may  contribute  to  sporozoite  binding  in  the 
liver. In contrast to CS, however, TRAP/SSP2 is detected 
as clusters in restricted regions of the parasite plasma mem- 
brane (27, 52,  53)  and its relative contribution to sporozo- 
ire adhesion to hepatocytes is not known. 
After  sequestration  by  HSPGs  in  the  liver,  sporozoites 
must  enter  hepatocytes  in  order  to  successfully complete 
their  development.  The  mechanism  by which  they  enter 
indicates that the efficiency of the RT reactions was equivalent in both 
groups. Molecular size markers (M); bp: 1,000, 750, 500, 300, 150, and 
50. (D) The photograph in B was analyzed  by densitometry. For each am- 
plification reaction, a target/competitor ratio was calculated and this ratio 
was used to determine the amount of parasite RNA per microgram of 
liver RNA. The mean for each group of mice is plotted with error bars 
showing the range of values calculated. cells  is  unknown  although  our  results  raise  the  possibility 
that sporozoites, like renmant lipoproteins,  are interiorized 
by LDLR  and/or  LRP.  Alternately,  the  attached  sporozo- 
itcs  may  use  their  own  actin-based  motility  system to  ac- 
tively  invade  hepatoctyes,  an  idea  supported  by videomi- 
croscopic  observations  (54)  and  recent  studies  of  cell 
invasion  by  Toxoplasma gondii  (55),  a  parasite  that belongs 
to ttae ~ame phylum as Plasmodium. 
Al~ unresolved issue is the anatomical localization  of the 
GAGs that bind  lipoprotein  remnants  and,  as suggested by 
the  present  results,  inalaria  sporozoites.  It  is generally  as- 
sumed  that  lipoprotem  renmants  traverse  the  fenestrated 
endothelium  of the  liver sinusoids  and  enter  the  space  of 
l)isse where  they are retained by HSPGs.  The diameter of 
~porozoites  (1  I,  tM),  however,  is  greater  than  the  average 
diameter of the fenestrae  (0.1  I~M; 56,  57),  making this an 
unlikely model for sporozoite attachment to hepatic HSPGs. 
Another  possibility  is  that  the  interaction  between  the 
GAG  chains  of  hepatic  HSPGs  with  their  physiologic 
ligands,  as  well  as  with  sporozoites,  takes place not  in  the 
space  of l)isse,  but  within  the  sinusoids.  If one  considers 
the fact that the space of Disse is a narrow, loose matrix of 
proteins  and  proteoglycans  rather  than  a  true  basement 
membrane,  it is possible that the long HSPG  GAG chains 
of the  hepatocytes  protrude  through  the  fenestrae  and  are 
in  direct  contact  with  the  blood  circulation.  This  model, 
strengthened by the finding that the bulk of the sulfation of 
the hepatcyte  HSPG GAG chains is found along the  distal 
portion  of the  molecules  (47),  would  greatly increase  the 
likelihood  of productive  encounters  between the positvely 
charged regions of the ligands and HSPGs. 
The  utilization  by sporozoite  and  lipoprotein  remnants 
of a  common  pathway  of retention  by the  liver is  unex- 
pected,  and brings together two different areas of research. 
Our findings  raise the  intriguing  possibility that the lower 
parasite densities  and fewer episodes of clinical malaria ob- 
served in neonates  (58,  59)  are,  at least in part,  due  to the 
high concentration  oflactoferrin (60) and the high fat con- 
tent of breast milk (61).  The present findings  thus provide 
new  perspectives  for  the  development  of  prophylactic 
agents against malaria, and for the understanding  of malaria 
pathology and epidemiology. 
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